<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02424669</url>
  </required_header>
  <id_info>
    <org_study_id>2014-19</org_study_id>
    <secondary_id>RCAPHM15_0132</secondary_id>
    <nct_id>NCT02424669</nct_id>
  </id_info>
  <brief_title>Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients</brief_title>
  <official_title>Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <brief_summary>
    <textblock>
      Amyotrophic Lateral Sclerosis (ALS) is the most common motor neuron diseases. It is
      considered as a rare disease with a prevalence of about 8 per 100,000 persons. Initiating in
      mid-life by progressive paralysis, it evolves rapidly into a generalized muscle wasting that
      leads irrevocably to death within 2 or 5 years of clinical onset.

      Since there is no cure for ALS, the management of the disease is supportive and palliative.
      Riluzole is the only drug that has been shown to extend survival by about three months. The
      identification of biomarkers sensitive to the progression of the disease might enhance the
      diagnostic and provide new drug targets.

      Dysfunction of the immune system is a pathological hallmark of ALS. Increased levels of
      interferon gamma (IFNgamma) were found in the serum and cerebrospinal fluid (CSF) of ALS
      patients. However, the cell origin as well as the pathogenic influence of this peripheral
      source of IFNg is unknown. Thus, IFNgamma might have a role in the pathogenic process of ALS
      and might be a potential biomarker of the disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ALS Functional rating Scale-revised (ALS FRS-R) score</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Amyotrophic Lateral Sclerosis (ALS)</condition>
  <arm_group>
    <arm_group_label>recently diagnosed ALS patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>not recently diagnosed ALS patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with peripheral neuropathy, recently diagnosed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ALS Functional rating Scale-revised (ALS FRS-R)</intervention_name>
    <arm_group_label>recently diagnosed ALS patients</arm_group_label>
    <arm_group_label>not recently diagnosed ALS patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>slow vital capacity</intervention_name>
    <arm_group_label>recently diagnosed ALS patients</arm_group_label>
    <arm_group_label>not recently diagnosed ALS patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <arm_group_label>recently diagnosed ALS patients</arm_group_label>
    <arm_group_label>not recently diagnosed ALS patients</arm_group_label>
    <arm_group_label>patients with peripheral neuropathy, recently diagnosed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cerebrospinal Fluid (CSF) sample</intervention_name>
    <arm_group_label>recently diagnosed ALS patients</arm_group_label>
    <arm_group_label>not recently diagnosed ALS patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Group 1 and Group 2:

          -  with sporadic ALS (without family history), recently diagnosed (onset of first
             symptoms &lt; 24 months) group 1, not recently diagnosed (onset of first symptoms &gt; 24
             months) group 2

          -  Who meet the laboratory-supported probable, probable or definite form of ALS according
             to the El Escorial criteria

          -  Suffering from the spinal form of ALS

        Group 3:

        - with an inflammatory peripheral neuropathy, or a non inflammatory peripheral neuropathy,
        recently diagnosed

        Exclusion Criteria:

          -  Familial form of ALS

          -  Bulbar form and respiratory onset form of ALS

          -  Subjects with a clinically significant history of unstable or severe cardiac,
             oncologic, hepatic or renal disease, or other medically significant illness.

          -  Subjects with significant cognitive impairment, clinical dementia, or psychiatric
             illness.

          -  Female of childbearing potential (apart of patient using adequate contraceptive
             measures), pregnant or breast feeding

          -  Suspected inability to complete the study follow-up (foreign workers, transient
             visitors, tourists or any others for whom follow-up evaluation is not assured)

          -  Participation in any other clinical study within 30 days prior to the Screening Visit

          -  Persons deprived of freedom by judicial or administrative decision, hospitalized
             without their consent or for other reasons than the research, under legal protection
             or unable to express their consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urielle Desalbres</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joelle Micallef</last_name>
    <email>joelle.micallef@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joelle Micallef</last_name>
      <email>joelle.micallef@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2015</study_first_submitted>
  <study_first_submitted_qc>April 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2015</study_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

